Jennifer M Specht
Jennifer M Specht, MD is an expert in Oncology at Fred Hutchinson Cancer Research Center (United States). As of October 2026, ScienceLeadR ranks Jennifer M Specht in the top 1% of experts worldwide for Breast Diseases and Breast Neoplasms. Jennifer M Specht has authored 191 publications, the most recent in 2026, and is an investigator in 19 clinical trials, 6 of them ongoing. SLR score: 910 (community average: 125). How the SLR is computed.
LeadR Profile
Oncology
Subspecialties: Nuclear Medicine - Medical Imaging - Dermatology
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 2007 - 2026
Number : 191
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
Clinical Studies 19
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Ongoing Clinical Trials
6 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Phase 1 2 Study of ETX 636 in Participants With Advanced Solid Tumors NCT06993844 — injections, cells, estrogen receptor antagonists, fulvestrant, estrogens, safety, breast neoplasms, pharmaceutical preparations, receptors, estrogen, carcinoma, squamous cell, uterine cervical neoplasms, ovary, antineoplastic agents, genital neoplasms, female, neoplasms, tablets, hereditary sensory and autonomic neuropathies, hormones, squamous cell carcinoma of head and neck, physiological effects of drugs, ovarian neoplasms, hormone antagonists, breast, estrogen antagonists, neoplasms by site, head and neck neoplasms, therapeutics, hormones, hormone substitutes, and hormone antagonists, mutation, breast diseases, endometrial neoplasms, pharmacokinetics, carcinoma, head, neck | Phase 1/Phase 2 | Recruiting | 2025 |
| 18F FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer NCT06502691 — cells, research design, deoxyglucose, guidelines as topic, poly(adp-ribose) polymerase inhibitors, poly(adp-ribose) polymerases, breast neoplasms, tomography, positron-emission tomography, practice guidelines as topic, neoplasms, ribose, biopsy, poly adenosine diphosphate ribose, positron emission tomography computed tomography, electronic health records, fluorodeoxyglucose f18, immune checkpoint inhibitors, breast, work, records, therapeutics, adenosine diphosphate ribose, carcinoma | Phase 1/Phase 2 | Recruiting | 2026 |
| Shorter Chemo Immunotherapy Without Anthracycline Drugs for Early Stage Triple Negative Breast Cancer NCT05929768 — taxes, injections, cells, quality of life, triple negative breast neoplasms, growth, blood, breast neoplasms, docetaxel, paclitaxel, pharmaceutical preparations, surgical procedures, operative, cyclophosphamide, doxorubicin, neoplasms, drug therapy, immunotherapy, breast, work, daunorubicin, anthracyclines, specimen handling, therapeutics, carboplatin, dna, chemotherapy, carcinoma | Phase 3 | Recruiting | 2023 |
| Pembrolizumab vs Observation in People With Triple negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab NCT05812807 — quality of life, triple negative breast neoplasms, blood, breast neoplasms, polymerase chain reaction, neoplasms, biopsy, drug therapy, breast, therapeutics, chemotherapy, carcinoma | Phase 3 | Recruiting | 2023 |
| Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard of Care for the Treatment of Patients With Advanced or Metastatic HR HER2 Breast Cancer (VIKTORIA 1) NCT05501886 — injections, fulvestrant, aromatase, aromatase inhibitors, breast neoplasms, neoplasms, tablets, neoplasm metastasis, breast, therapeutics | Phase 3 | Active not recruiting | 2022 |
LeadR Networks
Main global connection map